{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:53:07Z","timestamp":1794016387668,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BI 1711\/4-1"],"award-info":[{"award-number":["BI 1711\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We identified a subset of Chronic Lymphocytic Leukemia (CLL) patients with high Signaling Lymphocytic Activation Molecule Family (SLAMF) receptor-related signaling that showed an indolent clinical course. Since SLAMF receptors play a role in NK cell biology, we reasoned that these receptors may impact NK cell-mediated CLL immunity. Indeed, our experiments showed significantly decreased degranulation capacity of primary NK cells from CLL patients expressing low levels of SLAMF1 and SLAMF7. Since the SLAMF<jats:sup>low<\/jats:sup> signature was strongly associated with an unmutated CLL immunoglobulin heavy chain (IGHV) status in large datasets, we investigated the impact of SLAMF1 and SLAMF7 on the B cell receptor (BCR) signaling axis. Overexpression of SLAMF1 or SLAMF7 in IGHV mutated CLL cell models resulted in reduced proliferation and impaired responses to BCR ligation, whereas the knockout of both receptors showed opposing effects and increased sensitivity toward inhibition of components of the BCR pathway. Detailed molecular analyzes showed that SLAMF1 and SLAMF7 receptors mediate their BCR pathway antagonistic effects via recruitment of prohibitin-2 (PHB2) thereby impairing its role in signal transduction downstream the IGHV-mutant IgM-BCR. Together, our data indicate that SLAMF receptors are important modulators of the BCR signaling axis and may improve immune control in CLL by interference with NK cells.<\/jats:p>","DOI":"10.1038\/s41375-020-01025-z","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T10:44:26Z","timestamp":1598006666000},"page":"1073-1086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1963-0398","authenticated-orcid":false,"given":"Lisa","family":"von Wenserski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9789-5776","authenticated-orcid":false,"given":"Christoph","family":"Schulthei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schliffke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-1381","authenticated-orcid":false,"given":"Donjete","family":"Simnica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Willscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helwe","family":"Gerull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2984-6515","authenticated-orcid":false,"given":"Gerrit","family":"Wolters-Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Riecken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-7211","authenticated-orcid":false,"given":"Boris","family":"Fehse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Altfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nollau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-3004","authenticated-orcid":false,"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.beha.2016.08.004","volume":"29","author":"D Jeyakumar","year":"2016","unstructured":"Jeyakumar D, O\u2019Brien S. B cell receptor inhibition as a target for CLL therapy. Best Pract Res Clin Haematol. 2016;29:2\u201314.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med"},{"key":"1025_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88.","journal-title":"J Clin Oncol"},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328.","journal-title":"N Engl J Med"},{"key":"1025_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343.","journal-title":"N Engl J Med"},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1182\/blood-2006-11-056648","volume":"109","author":"C Ian Mockridge","year":"2007","unstructured":"Ian Mockridge C, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109:4424\u201331.","journal-title":"Blood"},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1182\/blood-2007-12-127688","volume":"112","author":"A Guarini","year":"2008","unstructured":"Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782\u201392.","journal-title":"Blood"},{"key":"1025_CR9","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Wang V, Kay NE, Hanson CA, O\u2019Brien SM, Barrientos JC, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with Chronic Lymphocytic Leukemia (CLL): a trial of the ECOG-ACRIN cancer. Blood. 2018;132 (Suppl 1):LBA4.","DOI":"10.1182\/blood-2018-120779"},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"a002469","DOI":"10.1101\/cshperspect.a002469","volume":"2","author":"A Veillette","year":"2010","unstructured":"Veillette A. SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol. 2010;2:a002469.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2018.10.020","volume":"204","author":"I Shachar","year":"2019","unstructured":"Shachar I, Barak A, Lewinsky H, Sever L, Radomir L. SLAMF receptors on normal and malignant B cells. Clin Immunol. 2019;204:23\u201330.","journal-title":"Clin Immunol"},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1080\/10428194.2016.1251593","volume":"58","author":"M Coma","year":"2017","unstructured":"Coma M, Tothova E, Guman T, Hajikova M, Giertlova M, Sarissky M. Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58:1726\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/mt.2008.6","volume":"16","author":"K Weber","year":"2008","unstructured":"Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral \u201cgene ontology\u201d (LeGO) vectors for functional gene analysis. Mol Ther. 2008;16:698\u2013706.","journal-title":"Mol Ther"},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u201387.","journal-title":"Science"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nm1365","volume":"12","author":"RJ Y\u00e1\u00f1ez-Mu\u00f1oz","year":"2006","unstructured":"Y\u00e1\u00f1ez-Mu\u00f1oz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 2006;12:348.","journal-title":"Nat Med"},{"key":"1025_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10934","volume":"7","author":"TC Cheong","year":"2016","unstructured":"Cheong TC, Compagno M, Chiarle R. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat Commun. 2016;7:10934.","journal-title":"Nat Commun"},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jim.2009.07.002","volume":"348","author":"E Schepers","year":"2009","unstructured":"Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Flow cytometric calcium flux assay: evaluation of cytoplasmic calcium kinetics in whole blood leukocytes. J Immunol Methods. 2009;348:74\u201382.","journal-title":"J Immunol Methods"},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1091\/mbc.E15-12-0844","volume":"27","author":"DI Kim","year":"2016","unstructured":"Kim DI, Jensen SC, Noble KA, Kc B, Roux KH, Motamedchaboki K, et al. An improved smaller biotin ligase for BioID proximity labeling. Mol Biol Cell. 2016;27:1188\u201396.","journal-title":"Mol Biol Cell"},{"key":"1025_CR19","doi-asserted-by":"crossref","unstructured":"Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15\u201322.","DOI":"10.1016\/j.jim.2004.08.008"},{"key":"1025_CR20","doi-asserted-by":"crossref","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer; 2000. p. 350.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.molcel.2007.05.031","volume":"26","author":"K Machida","year":"2007","unstructured":"Machida K, Thompson CM, Dierck K, Jablonowski K, K\u00e4rkk\u00e4inen S, Liu B, et al. High-throughput phosphotyrosine profiling using SH2 domains. Mol Cell. 2007;26:899\u2013915.","journal-title":"Mol Cell"},{"key":"1025_CR22","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood-2017-06-788166","volume":"131","author":"S Schliffke","year":"2018","unstructured":"Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, et al. The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. Blood. 2018;131:1755\u20138.","journal-title":"Blood"},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00281-009-0193-0","volume":"32","author":"C Detre","year":"2010","unstructured":"Detre C, Keszei M, Romero X, Tsokos GC, Terhorst C. SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Semin Immunopathol. 2010;32:157\u201371.","journal-title":"Semin Immunopathol"},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coi.2015.11.003","volume":"38","author":"N Wu","year":"2016","unstructured":"Wu N, Veillette A. SLAM family receptors in normal immunity and immune pathologies. Curr Opin Immunol. 2016;38:45\u201351.","journal-title":"Curr Opin Immunol"},{"key":"1025_CR25","doi-asserted-by":"crossref","unstructured":"Baba Y, Kurosaki T. Role of calcium signaling in B cell activation and biology. Cham: Springer; 2015. p. 143\u201374.","DOI":"10.1007\/82_2015_477"},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/1521-4141(200206)32:6<1640::AID-IMMU1640>3.0.CO;2-S","volume":"32","author":"SG Tangye","year":"2002","unstructured":"Tangye SG, Weerdt BCMvd, Avery DT, Hodgkin PD. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Eur J Immunol. 2002;32:1640.","journal-title":"Eur J Immunol"},{"key":"1025_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nri1761","volume":"6","author":"A Veillette","year":"2006","unstructured":"Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol. 2006;6:56\u201366.","journal-title":"Nat Rev Immunol"},{"key":"1025_CR28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1083\/jcb.201112098","volume":"196","author":"KJ Roux","year":"2012","unstructured":"Roux KJ, Kim DI, Raida M, Burke B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J Cell Biol. 2012;196:801\u201310.","journal-title":"J Cell Biol"},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"39844","DOI":"10.1074\/jbc.M110.164509","volume":"285","author":"LL Paris","year":"2010","unstructured":"Paris LL, Hu J, Galan J, Ong SS, Martin VA, Ma H, et al. Regulation of Syk by phosphorylation on serine in the linker insert. J Biol Chem. 2010;285:39844\u201354.","journal-title":"J Biol Chem"},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4049\/jimmunol.1201646","volume":"190","author":"CR Lucas","year":"2013","unstructured":"Lucas CR, Cordero-Nieves HM, Erbe RS, McAlees JW, Bhatia S, Hodes RJ, et al. Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J Immunol. 2013;190:723\u201336.","journal-title":"J Immunol"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/j.1460-2075.1994.tb06689.x","volume":"13","author":"M Terashima","year":"1994","unstructured":"Terashima M, Kim KM, Adachi T, Nielsen PJ, Reth M, Kohler G, et al. The IgM antigen receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein. EMBO J. 1994;13:3782\u201392.","journal-title":"EMBO J"},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495.","journal-title":"Nat Immunol"},{"key":"1025_CR33","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419\u201327.","journal-title":"Blood"},{"key":"1025_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1172\/JCI83013","volume":"126","author":"C Bologna","year":"2016","unstructured":"Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, et al. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. J Clin Investig. 2016;126:181\u201394.","journal-title":"J Clin Investig"},{"key":"1025_CR35","doi-asserted-by":"publisher","first-page":"e28277","DOI":"10.1371\/journal.pone.0028277","volume":"6","author":"CD Schweighofer","year":"2011","unstructured":"Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, et al. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PloS One. 2011;6:e28277.","journal-title":"PloS One"},{"key":"1025_CR36","doi-asserted-by":"crossref","unstructured":"Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, et al. Slamf-1\/CD150 is a signaling receptor expressed by a subset of chronic lymphocytic leukemia patients characterized by a favorable prognosis. Blood. 2012;120:1770.","DOI":"10.1182\/blood.V120.21.1770.1770"},{"key":"1025_CR37","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","volume":"175","author":"I Tassi","year":"2005","unstructured":"Tassi I, Colonna M, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol. 2005;175:7996\u20138002.","journal-title":"J Immunol"},{"key":"1025_CR38","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/onc.2013.31","volume":"33","author":"I Binsky-Ehrenreich","year":"2014","unstructured":"Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-Halevy I, et al. CD84 is a survival receptor for CLL cells. Oncogene. 2014;33:1006\u201316.","journal-title":"Oncogene"},{"key":"1025_CR39","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810\u20137.","journal-title":"Blood"},{"key":"1025_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/leu.2010.240","volume":"25","author":"M Le Garff-Tavernier","year":"2011","unstructured":"Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011;25:101\u20139.","journal-title":"Leukemia"},{"key":"1025_CR41","doi-asserted-by":"crossref","unstructured":"Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. OncoImmunology. 2017;6:e1339853.","DOI":"10.1080\/2162402X.2017.1339853"},{"key":"1025_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fimmu.2016.00454","volume":"7","author":"D Sanchez-Martinez","year":"2016","unstructured":"Sanchez-Martinez D, Lanuza PM, Gomez N, Muntasell A, Cisneros E, Moraru M, et al. Activated allogeneic NK cells preferentially kill poor prognosis B-cell chronic lymphocytic leukemia cells. Front Immunol. 2016;7:454.","journal-title":"Front Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-01025-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-01025-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-01025-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T23:11:10Z","timestamp":1629501070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-01025-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-01025-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}